论文部分内容阅读
最近发表的一些体外研究发现,正常细胞系中长效胰岛素类似物的IGF-I受体亲和力与人胰岛素相似;在某些肿瘤细胞系中,长效胰岛素类似物的促有丝分裂作用高于人胰岛素。而临床上胰岛素类似物注射入人体内后会迅速发生转化,如甘精胰岛素(Gla)在体内循环中则主要以代谢产物M1的形式存在,而M1的促有丝分裂潜能低于人胰岛素。关于糖尿病视网膜病变的临床研究提示,在体内的Gla的确不增加IGF-I受体亲和力。而且,最新的临床研究也未提示Gla会增加肿瘤风险。因此国际多个研究机构均声明,患者可根据处方说明或咨询医师使用长效胰岛素类似物。
Several recent in vitro studies have found that IGF-I receptor affinity of long-acting insulin analogs in normal cell lines is similar to that of human insulin; in some tumor cell lines, long-acting insulin analogs have greater mitogenic effects than human insulin . In clinical practice, insulin analogues are rapidly transformed after being injected into the human body. For example, insulin (Gla) is mainly present in the form of metabolite M1 in vivo while M1 has lower mitogenic potential than human insulin. Clinical studies on diabetic retinopathy have suggested that Gla does not increase IGF-I receptor affinity in vivo. Moreover, the latest clinical studies have not prompted Gla will increase the tumor risk. Therefore, a number of international research institutions have stated that patients can use the long-acting insulin analogues according to prescription instructions or consult a physician.